Growth with Growth Hormone in Short Stature Children
On October 18, 2005, Newsday.com, published the following article by Ellen Mitchell, a free lance reporter, entitled "A Tall Order: For some short children growth hormones are the answer." In the article, Ms. Mitchell tells of the use of recombinant (biosynthetic) growth hormone in children with short stature to achieve growth, highlighting issues and personal success stories involved in growth hormone replacement therapy.

FDA Approves Expanded Use of rGH
On July 26, 2003, the federal Food and Drug Administration approved a supplemental new drug application by Eli Lilly & Company for the use of recombinant human growth hormone to treat children who are healthy but unusually short (defined as an adult height of less than 5 feet 3 inches for men and 4 feet 11 inches for women) without a known cause.

International Consensus on Deficiency & Management of SGA with rGH
Pfizer has announced in the June 2003 issue of Pediatrics, the official journal of the American Academy of Pediatrics, the publication of an international consensus statement on the Deficiency and management of persistent short stature in children born small for gestational age (SGA) who do not exhibit catch-up growth by age two.

FDA Advisory Committee Recommends FDA approval of Expanded Use of rGH
Application (sNDA) by Eli Lilly and Company for recombinant growth hormone for non-GHD boys and girls who are exceedingly short stature, and who are not likely to reach a reasonably normal adult height. Nicole Costa, daughter of Patricia D (Patti) Costa, Executive Director of HGF, and Patti Costa, testified in favor of the sNDA.